97 related articles for article (PubMed ID: 22753738)
1. Mafosfamide as a new anticancer agent: preclinical investigations and clinical trials.
Mazur L; Opydo-Chanek M; Stojak M; Wojcieszek K
Anticancer Res; 2012 Jul; 32(7):2783-9. PubMed ID: 22753738
[TBL] [Abstract][Full Text] [Related]
2. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial.
Blaney SM; Balis FM; Berg S; Arndt CA; Heideman R; Geyer JR; Packer R; Adamson PC; Jaeckle K; Klenke R; Aikin A; Murphy R; McCully C; Poplack DG
J Clin Oncol; 2005 Mar; 23(7):1555-63. PubMed ID: 15735131
[TBL] [Abstract][Full Text] [Related]
3. Oxazaphosphorine effects in L 5222 rat leukemia.
Pohl J; Reissmann T; Voegeli R
Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):589-94. PubMed ID: 3437788
[TBL] [Abstract][Full Text] [Related]
4. Glufosfamide as a new oxazaphosphorine anticancer agent.
Mazur L; Opydo-Chanek M; Stojak M
Anticancer Drugs; 2011 Jul; 22(6):488-93. PubMed ID: 21427562
[TBL] [Abstract][Full Text] [Related]
5. Trofosfamide in the palliative treatment of cancer: a review of the literature.
Latz D; Nassar N; Frank R
Onkologie; 2004 Dec; 27(6):572-6. PubMed ID: 15591719
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001).
Blaney SM; Boyett J; Friedman H; Gajjar A; Geyer R; Horowtiz M; Hunt D; Kieran M; Kun L; Packer R; Phillips P; Pollack IF; Prados M; Heideman R
J Clin Oncol; 2005 Jan; 23(3):525-31. PubMed ID: 15659498
[TBL] [Abstract][Full Text] [Related]
7. Preclinical and early clinical trial with mafosfamide as immune modulator.
Klein HO; Kreysch HG; Coerper C; Voigt P; Ruff I
Methods Find Exp Clin Pharmacol; 1987 Sep; 9(9):627-40. PubMed ID: 3325719
[TBL] [Abstract][Full Text] [Related]
8. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
9. Successful chemoimmunotherapy of murine L1210 lymphatic leukemia with cyclophosphamide and mafosfamide-treated leukemia cells.
Kawalec M; Skórski T; Kawiak J
Invest New Drugs; 1988 Sep; 6(3):169-72. PubMed ID: 3192382
[TBL] [Abstract][Full Text] [Related]
10. Cell-cycle disruptions and apoptosis induced by the cyclophosphamide derivative mafosfamide.
Davidoff AN; Mendelow BV
Exp Hematol; 1993 Jul; 21(7):922-7. PubMed ID: 8319782
[TBL] [Abstract][Full Text] [Related]
11. Design of new oxazaphosphorine anticancer drugs.
Liang J; Huang M; Duan W; Yu XQ; Zhou S
Curr Pharm Des; 2007; 13(9):963-78. PubMed ID: 17430192
[TBL] [Abstract][Full Text] [Related]
12. Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture.
Brock N
Cancer Res; 1989 Jan; 49(1):1-7. PubMed ID: 2491747
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias. The Italian Study Group.
Rizzoli V; Mangoni L
Prog Clin Biol Res; 1990; 333():21-36; discussion 37-8. PubMed ID: 2308982
[TBL] [Abstract][Full Text] [Related]
14. New application of a stabilized active cyclophosphamide derivative (mafosfamide, ASTA Z 7654)--immunogenic properties of lymphatic leukemia L 1210 cells treated in vitro with the drug.
Skórski T; Kawalec M
Invest New Drugs; 1987; 5(2):167-9. PubMed ID: 3654151
[TBL] [Abstract][Full Text] [Related]
15. Biologic and therapeutic efficacy of mafosfamide in patients with metastatic renal cell carcinoma.
Schomburg A; Menzel T; Hadam M; Duensing S; Körfer A; Kirchner H; Poliwoda H; Atzpodien J
Mol Biother; 1992 Jun; 4(2):58-65. PubMed ID: 1515095
[TBL] [Abstract][Full Text] [Related]
16. Phase-I study of mafosfamide-cyclohexylamine (ASTA-Z-7557, NSC 345 842) and limited phase-I data on mafosfamide-lysine.
Bruntsch U; Groos G; Hiller TA; Wandt H; Tigges FJ; Gallmeier WM
Invest New Drugs; 1985; 3(3):293-6. PubMed ID: 4066222
[TBL] [Abstract][Full Text] [Related]
17. Autologous marrow transplantation in acute lymphoblastic leukemia: control of residual disease with mafosfamide and induction of syngeneic GVHD with cyclosporin. The Italian Mafosfamide Study Group.
Rizzoli V; Carella AM; Carlo-Stella C; Mangoni L
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():76-8. PubMed ID: 2202474
[No Abstract] [Full Text] [Related]
18. Activated lymphocytes in the marrow cell suspension decrease the mafosfamide-induced CFU-GM cytotoxicity.
Woźny T; Sawiński K; Kozłowska-Skrzypczak M; Hansz J
Acta Haematol Pol; 1995; 26(4):367-75. PubMed ID: 8571738
[TBL] [Abstract][Full Text] [Related]
19. High-dose selection with mafosfamide results in sensitivity to DNA cross-linking agents: characterization of hypersensitive cell lines.
Fritz G; Hengstler JG; Kaina B
Cancer Res; 1997 Feb; 57(3):454-60. PubMed ID: 9012473
[TBL] [Abstract][Full Text] [Related]
20. Protection of mammalian cells against chemotherapeutic agents thiotepa, 1,3-N,N'-bis(2-chloroethyl)-N-nitrosourea, and mafosfamide using the DNA base excision repair genes Fpg and alpha-hOgg1: implications for protective gene therapy applications.
Xu Y; Hansen WK; Rosenquist TA; Williams DA; Limp-Foster M; Kelley MR
J Pharmacol Exp Ther; 2001 Mar; 296(3):825-31. PubMed ID: 11181913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
